DAKTRONICS INC /SD/ (DAKT) Form 8-K — Sep 2, 2026
Daktronics reported fiscal 2027 first-quarter net sales of $234.6 million, up 7.1% from $219.0 million a year earlier despite one fewer week in the quarter, with diluted EPS of $0.40, up 21.2% from $0.33 — the company's highest quarterly diluted EPS in the past 12 quarters. Net income rose to $19.4 million from $16.5 million, with operating margin steady at 10.6% and gross margin improving to 30.5%. Product backlog ended the quarter at $311.3 million, the sixth consecutive quarter above $300 million, although new orders fell 19.6% year over year to $191.8 million as a few substantial transactions are expected to book in Q2.
Key figures
- Eps
- 0.4
- Revenue
- 234565000
- Net Income
- 19430000
- Total Debt
- 10500000
- Revenue Yoy
- 7.1%
- Total Assets
- 607380000
- Cash Position
- 154585000
- Ebitda
- $29.6 million vs $28.1 million prior year
- New Orders
- $191.8 million, down 19.6% from $238.5 million
- Gross Margin
- 30.5% vs 29.7% prior year
- Free Cash Flow
- $27.5 million vs $22.0 million prior year
- Ceo Base Salary
- $600,000 effective September 13, 2026
- Product Backlog
- $311.3 million, 6th consecutive quarter above $300 million (vs $360.3 million a year ago)
- Operating Income
- $24.9 million, up 7.2% YoY
- Operating Margin
- 10.6%
- Effective Tax Rate
- 24.3% vs 25.9% prior year
- Fiscal2028 Targets
- 7-10% revenue CAGR, 10-12% operating margin, 17-20% ROIC
- Operating Cash Flow
- $31.4 million vs $26.1 million prior year
- Q1 Share Repurchases
- $4.4 million; 225.5 thousand shares at $19.56 VWAP
- Working Capital Ratio
- 2.2 to 1
- Senior Credit Facility
- $71.5 million; no advances outstanding on loan portion
- New Buyback Authorization
- $34.5 million under Fiscal 2027 Repurchase Program
- Weighted Avg Diluted Shares
- 48901000
Price after filing
Close on the filing date to close N calendar days later (from $19.36). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.